JP2011528656A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528656A5
JP2011528656A5 JP2011518816A JP2011518816A JP2011528656A5 JP 2011528656 A5 JP2011528656 A5 JP 2011528656A5 JP 2011518816 A JP2011518816 A JP 2011518816A JP 2011518816 A JP2011518816 A JP 2011518816A JP 2011528656 A5 JP2011528656 A5 JP 2011528656A5
Authority
JP
Japan
Prior art keywords
drug delivery
delivery system
administered
eye
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528656A (ja
Filing date
Publication date
Priority claimed from US12/176,238 external-priority patent/US8821870B2/en
Application filed filed Critical
Publication of JP2011528656A publication Critical patent/JP2011528656A/ja
Publication of JP2011528656A5 publication Critical patent/JP2011528656A5/ja
Pending legal-status Critical Current

Links

JP2011518816A 2008-07-18 2009-07-13 萎縮性加齢性黄斑変性の処置方法 Pending JP2011528656A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/176,238 2008-07-18
US12/176,238 US8821870B2 (en) 2008-07-18 2008-07-18 Method for treating atrophic age related macular degeneration
PCT/US2009/050373 WO2010009034A2 (en) 2008-07-18 2009-07-13 Method for treating atrophic age related macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014169846A Division JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法

Publications (2)

Publication Number Publication Date
JP2011528656A JP2011528656A (ja) 2011-11-24
JP2011528656A5 true JP2011528656A5 (enExample) 2012-08-16

Family

ID=41530477

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011518816A Pending JP2011528656A (ja) 2008-07-18 2009-07-13 萎縮性加齢性黄斑変性の処置方法
JP2014169846A Expired - Fee Related JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法
JP2016124732A Expired - Fee Related JP6132964B2 (ja) 2008-07-18 2016-06-23 萎縮性加齢性黄斑変性の処置方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014169846A Expired - Fee Related JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法
JP2016124732A Expired - Fee Related JP6132964B2 (ja) 2008-07-18 2016-06-23 萎縮性加齢性黄斑変性の処置方法

Country Status (11)

Country Link
US (3) US8821870B2 (enExample)
EP (4) EP3524270B1 (enExample)
JP (3) JP2011528656A (enExample)
KR (1) KR20110047196A (enExample)
CN (2) CN102159246A (enExample)
AU (1) AU2009271168B2 (enExample)
BR (1) BRPI0915981A2 (enExample)
CA (1) CA2731270C (enExample)
ES (3) ES2720882T3 (enExample)
RU (3) RU2521338C9 (enExample)
WO (1) WO2010009034A2 (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
ES2468827T3 (es) * 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
US9889088B2 (en) * 2010-01-21 2018-02-13 Allergan, Inc. Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
US20130210876A1 (en) * 2010-01-21 2013-08-15 Allergan, Inc Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
KR101845107B1 (ko) 2010-08-17 2018-04-03 오에이치알 파마서티컬, 인코포레이티드 스쿠알라민 안약 제제
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2671589A4 (en) * 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
HRP20192276T1 (hr) * 2011-06-10 2020-05-15 Ramscor, Inc. Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
EP2720722A4 (en) 2011-06-16 2014-12-03 Univ Hong Kong Science & Techn MOLECULAR WITH SEVERAL VINYL SULPHONES
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
RU2014105495A (ru) * 2011-07-19 2015-08-27 Уилфред ДЖЕФФРИС Способы диагностики и лечения болезни альцгеймера
PT2755600T (pt) 2011-09-16 2021-04-19 Forsight Vision4 Inc Aparelhos de troca de fluidos
WO2013074840A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
RU2676102C2 (ru) * 2012-09-27 2018-12-26 Аллерган, Инк. Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков
MX373894B (es) 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CN102988301A (zh) * 2012-12-26 2013-03-27 温州医学院 一种含贝伐单抗的长效缓释微球的制备方法
US9254409B2 (en) 2013-03-14 2016-02-09 Icon Health & Fitness, Inc. Strength training apparatus with flywheel and related methods
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US20160166701A1 (en) * 2013-07-05 2016-06-16 Therakine Biodelivery Gmbh Delivery composition for topical applications and injections and ophthalmic formulations, methods for manufacturing thereof, and methods for delivery of a drug-delivery composition
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
EP3071181B1 (en) * 2013-11-18 2021-03-24 Formycon AG Pharmaceutical composition of an anti-vegf antibody
EP3623020B1 (en) 2013-12-26 2024-05-01 iFIT Inc. Magnetic resistance mechanism in a cable machine
US10426989B2 (en) 2014-06-09 2019-10-01 Icon Health & Fitness, Inc. Cable system incorporated into a treadmill
EP3157598A4 (en) 2014-06-20 2018-05-16 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
CA2977738A1 (en) * 2015-02-26 2016-09-01 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CN108348572B (zh) 2015-03-31 2021-06-29 日东制药株式会社 含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
JP6887377B2 (ja) * 2015-05-29 2021-06-16 生化学工業株式会社 グリコサミノグリカン誘導体とケモカイン受容体活性調節材とを含む組成物
US10940360B2 (en) 2015-08-26 2021-03-09 Icon Health & Fitness, Inc. Strength exercise mechanisms
US10953305B2 (en) 2015-08-26 2021-03-23 Icon Health & Fitness, Inc. Strength exercise mechanisms
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
PE20181363A1 (es) 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
JP6986758B2 (ja) * 2016-02-08 2021-12-22 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー−生体接着性ポリマーヒドロゲルナノ接着剤およびその使用
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
CN115951066A (zh) * 2016-02-29 2023-04-11 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
JP6664115B2 (ja) * 2016-03-15 2020-03-13 原　英彰 アフリベルセプトによる網膜保護作用
US10441840B2 (en) 2016-03-18 2019-10-15 Icon Health & Fitness, Inc. Collapsible strength exercise machine
US10293211B2 (en) 2016-03-18 2019-05-21 Icon Health & Fitness, Inc. Coordinated weight selection
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10252109B2 (en) 2016-05-13 2019-04-09 Icon Health & Fitness, Inc. Weight platform treadmill
US11400080B2 (en) 2016-05-25 2022-08-02 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
US10661114B2 (en) 2016-11-01 2020-05-26 Icon Health & Fitness, Inc. Body weight lift mechanism on treadmill
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
AR111190A1 (es) 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
US11918657B2 (en) 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
CN111655206B (zh) 2017-11-21 2022-10-14 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
AU2019256289A1 (en) * 2018-04-17 2020-11-12 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab for use of treating diseases
KR102192768B1 (ko) * 2018-12-07 2020-12-18 전북대학교산학협력단 식나무 추출물을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물
DE102019112917B4 (de) * 2019-05-16 2021-07-22 Carl Zeiss Meditec Ag Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat
CN109966243A (zh) * 2019-05-17 2019-07-05 上海第二工业大学 一种用于眼底黄斑治疗的释药型凝胶及其制备方法
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
CA3144986A1 (en) * 2019-06-27 2020-12-30 University Of Florida Research Foundation, Incorporated Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
PT3861985T (pt) 2020-02-06 2023-08-03 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
WO2021262916A1 (en) * 2020-06-26 2021-12-30 Purdue Research Foundation Pharmaceutical formulations of griseofulvin for long-term ocular delivery
US20240058308A1 (en) * 2021-01-12 2024-02-22 The Regents Of The University Of Michigan Treatment and prevention of dry macular degeneration
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
PE20260040A1 (es) 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2446405A (en) 1945-10-31 1948-08-03 Hazeltine Research Inc Tunable ultra high frequency resonator system
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
HK1042052A1 (zh) * 1999-02-08 2002-08-02 Human Genome Sciences, Inc. 内皮血管生长因子-2
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
JP2003511204A (ja) 1999-10-21 2003-03-25 アルコン，インコーポレイティド テノン下薬剤送出
RU2354398C2 (ru) * 2001-07-13 2009-05-10 Оксиджин, Инк. Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
US20040229960A1 (en) 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
CN1301692C (zh) 2002-09-18 2007-02-28 阿勒根公司 眼植入物导入的器械
NZ540186A (en) * 2002-10-31 2008-03-28 Celgene Corp Composition for the treatment of macular degeneration
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8003124B2 (en) * 2005-04-08 2011-08-23 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
NZ566774A (en) * 2005-09-07 2011-11-25 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2616296T3 (es) 2005-12-02 2017-06-12 (Osi) Eyetech, Inc. Micropartículas de liberación controlada
US20090221684A1 (en) * 2005-12-22 2009-09-03 Trustees Of Boston University Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
JP2009524684A (ja) * 2006-01-26 2009-07-02 アキュセラ， インコーポレイテッド 眼疾患および障害の治療のための組成物および方法
WO2007128526A2 (en) 2006-05-04 2007-11-15 Fovea Pharmaceuticals Sa Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
EP2056812A1 (en) * 2006-08-31 2009-05-13 Abraxis BioScience, LLC Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100111963A1 (en) 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2968112C (en) 2016-05-26 2025-09-23 Op-Hygiene Ip Gmbh MAINTENANCE OF A DISPENSER INTENDED FOR AN INSTALLATION WITH MULTIPLE BATHROOMS
US11138621B2 (en) 2019-05-23 2021-10-05 Capital One Services, Llc Normalization grid

Similar Documents

Publication Publication Date Title
JP2011528656A5 (enExample)
JP6700348B2 (ja) 持続型薬物送達インプラント
RU2018133133A (ru) Способ лечения атрофической возрастной макулярной дегенерации
JP2008540552A5 (enExample)
US20240082150A1 (en) Ocular compositions
JP2018500394A5 (enExample)
RU2672596C2 (ru) Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
Goyal et al. Current nanotechnological strategies for treating glaucoma
JP2007535552A5 (enExample)
RU2017123358A (ru) Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
JP2017537985A5 (enExample)
CA2772795A1 (en) Injectable aqueous ophthalmic composition and method of use therefor
JP2009535422A5 (enExample)
JP2013526572A5 (enExample)
BRPI0708622A2 (pt) terapia ocular usando agentes que ativam a sirtuina
JP2007535564A5 (enExample)
CN103990185B (zh) 一种卡拉胶和明胶微球栓塞剂及其制备方法
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
JP2013523748A5 (enExample)
WO2005018608A1 (ja) 微粒子テノン嚢下投与ドラッグデリバリーシステム
CA3124280A1 (en) Ocular compositions
JP2024539445A5 (enExample)
JP2005132737A (ja) 埋込型製剤の薬物保持担体
RU2021117158A (ru) Улучшенные агрегированные микрочастицы